PO-1676: Blood biomarkers for cognitive damage after PCI; an exploratory analysis of the HA-PCI phase 3 trial. - Compter, I.; Oldoni, E.; Houben, R.; Van der Weijst, L.; De Ruiter, M.; Goris, A.; Holt, M.; Deprez, S.; Lambrecht, M.; Lievens, Y.; Van Meerbeeck, J.P.; Schagen, S.B.; et al. (Radiotherapy & Oncology, 2020)